As the son of an engineer and a literature professor, I inherited a passion for a rigorous, number-based understanding of reality and a deep fascination with complex human experiences. This led me to pursue medicine and psychiatry—and a quest to apply innovative neuroscientific methods to the search for novel treatments for severe mood disorders, such as depression and bipolar disorder.
I am an associate professor of psychiatry at NYU School of Medicine. I am also director of clinical research at the Nathan Kline Institute for Psychiatric Research. My research has led to the validation of novel treatments for patients who have severe mood and anxiety disorders, including pharmacological treatments such as ketamine and other glutamatergic drugs, and devices such as novel forms of magnetic stimulation. I also use neuroimaging, neurophysiology, and neurocognitive tests to evaluate structural, biochemical, and functional brain abnormalities in people who have mood disorders, and my research explores how these brain abnormalities may impact clinical treatment.
I have significant clinical and research expertise in the service of patients who have treatment-resistant forms of depression and bipolar disorder. However, my knowledge of treatments and neuroscience would be insufficient if not matched by a passionate desire to understand people’s unique history and suffering, and to develop mutual trust with each person I am treating. I aim not only to alleviate severe pain and suffering, but also to restore my patients’ hope in their futures, and their sense of purpose and effectiveness.
In addition to having been awarded several research prizes, I am honored to have been recognized by my peers as one of “America’s Top Doctors” in all editions of “Top Doctors” since 2005, and as one of Castle Connolly’s “Top Doctors” for psychiatry in the New York Metro Area since 2015.
Conditions and Treatments
- acute stress disorder
- anxiety disorders
- attention deficit disorder in adults
- attention deficit hyperactivity disorder
- bipolar disorder
- cognitive disorder
- generalized anxiety disorder
- mood disorder
- obsessive compulsive disorder
- panic disorder
- post-traumatic stress disorder
- social anxiety disorder
- American Board of Psychiatry & Neurology - Psychiatry, 2001
Education and Training
- Residency, Massachusetts General Hospital / Harvard Medical School, Psychiatry, 2000
- MD from Carol Davila University, 1992
Is this your profile?Edit profile
Insurance Plans Accepted
This provider accepts the following insurance plans.
- Aetna EPO (AMEX employees)
- Aetna POS (American Express Employer)
Blue Cross Blue Shield
- BCBS EPO (BlackRock Employees)
- BCBS EPO - Empire EPO (NYU Langone Employees)
- BCBS EPO - Empire EPO (Sunset Park/Family Health Center Employees)
- BCBS EPO - Empire NYU Care (NYU Langone Employees)
- BCBS EPO - Empire NYU Care (Sunset Park/Family Health Center Employees)
- BCBS PPO (BlackRock Employees)
- BCBS PPO - Empire PPO (Sunset Park/Family Health Center Employees)
- United Healthcare Choice (AMEX employees)
- United Healthcare Choice (Blackrock employees)
- United Healthcare Choice (CBS employees)
- United Healthcare EPO (NYU Langone Health Employees)
- United Healthcare Indemnity (NYU Langone Health Employees)
- United Healthcare Plus (NYU Langone Health Employees)
- United Healthcare Value, Advantage and HDHP (New York University employees)
Locations and Appointments
NYU Psychiatry Associates
1 Park Avenue, 8th Floor, New York, NY 10016
Clinical Trials and Research Studies
A Pilot Phase II Open-Label Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder
Grant Report on the Transcranial near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE) Study
Photonics. 2023 Jan 01; 10(1):?-?
Psychiatric clinics of North America. 2023 Jan 01; ?-?
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis
Journal of clinical psychiatry. 2022 Dec 12; 84(1):